X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8640) 8640
Newspaper Article (273) 273
Book Chapter (58) 58
Newsletter (34) 34
Magazine Article (21) 21
Dissertation (9) 9
Book Review (2) 2
Government Document (2) 2
Publication (2) 2
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (5907) 5907
humans (5836) 5836
prostate cancer (2997) 2997
animals (2917) 2917
androgens (2659) 2659
prostatic neoplasms - drug therapy (2198) 2198
female (1984) 1984
androgen antagonists - therapeutic use (1825) 1825
oncology (1795) 1795
testosterone (1726) 1726
aged (1635) 1635
middle aged (1499) 1499
urology & nephrology (1368) 1368
androgen antagonists - administration & dosage (1328) 1328
cancer (1313) 1313
endocrinology & metabolism (1304) 1304
androgen receptor (1278) 1278
prostatic neoplasms - pathology (1233) 1233
rats (1130) 1130
care and treatment (1113) 1113
research (939) 939
adult (935) 935
treatment outcome (928) 928
mice (863) 863
metastasis (809) 809
men (805) 805
prostate (774) 774
aged, 80 and over (760) 760
health aspects (740) 740
receptors, androgen - metabolism (733) 733
androgen antagonists - adverse effects (732) 732
androgen antagonists - pharmacology (726) 726
testosterone - blood (687) 687
estrogen (686) 686
expression (666) 666
castration (643) 643
hormones (618) 618
analysis (616) 616
pharmacology & pharmacy (615) 615
prostate-specific antigen - blood (613) 613
therapy (608) 608
orchiectomy (599) 599
prostatic neoplasms - therapy (577) 577
cancer therapies (574) 574
antineoplastic agents, hormonal - therapeutic use (565) 565
androgen (557) 557
chemotherapy (551) 551
urology (551) 551
cell line, tumor (546) 546
risk factors (543) 543
prostatic neoplasms - metabolism (536) 536
carcinoma (502) 502
dose-response relationship, drug (501) 501
time factors (495) 495
flutamide (491) 491
gene expression (491) 491
androgen deprivation therapy (486) 486
medicine & public health (475) 475
apoptosis (469) 469
physiological aspects (468) 468
androgens - metabolism (425) 425
prostatic neoplasms - blood (424) 424
antineoplastic agents, hormonal - administration & dosage (417) 417
abridged index medicus (416) 416
clinical trials (416) 416
receptors, androgen - genetics (416) 416
tumors (413) 413
prostatic neoplasms - mortality (412) 412
testosterone - pharmacology (410) 410
radiotherapy (408) 408
survival (408) 408
neurosciences (402) 402
antineoplastic combined chemotherapy protocols - therapeutic use (399) 399
drug administration schedule (396) 396
radical prostatectomy (395) 395
drug therapy (391) 391
antineoplastic agents - therapeutic use (382) 382
disease progression (380) 380
pregnancy (377) 377
quality of life (369) 369
cell biology (368) 368
androgens - pharmacology (361) 361
gene-expression (361) 361
androgen-deprivation therapy (357) 357
rats, sprague-dawley (357) 357
medicine (356) 356
proteins (355) 355
biochemistry & molecular biology (349) 349
prostatic neoplasms - surgery (348) 348
review (340) 340
estradiol (339) 339
growth (336) 336
combined modality therapy (334) 334
patients (334) 334
prostatic neoplasms, castration-resistant - drug therapy (334) 334
double-blind (330) 330
neoplasm staging (330) 330
prostate-cancer (330) 330
docetaxel (328) 328
prognosis (327) 327
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8765) 8765
Japanese (123) 123
German (108) 108
French (44) 44
Russian (31) 31
Spanish (22) 22
Italian (13) 13
Chinese (11) 11
Hungarian (9) 9
Portuguese (8) 8
Polish (6) 6
Ukrainian (5) 5
Czech (4) 4
Norwegian (4) 4
Bulgarian (3) 3
Danish (3) 3
Swedish (3) 3
Croatian (2) 2
Afrikaans (1) 1
Dutch (1) 1
Hebrew (1) 1
Persian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 352 - 360
The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,... 
ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | CLINICAL-TRIALS | DOUBLE-BLIND | LEUPROLIDE ACETATE | DOCETAXEL | CHEMOTHERAPY | NEOADJUVANT | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Androgen Antagonists - therapeutic use | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Prednisone | Research | Prostate cancer | Medical research | Prostate-specific antigen | Clinical trials | Metastasis | Patients | Cancer therapies | Metastases | Androgens | Chemotherapy | Pain | Castration | Medical prognosis | Hypokalemia | Death | Prostate | Abiraterone Acetate/administration & dosage | Prednisolone/administration & dosage | Androgen Antagonists/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Neoplasm Metastasis/drug therapy | Steroid 17-alpha-Hydroxylase/antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Klinisk medicin | Clinical Medicine | Prostatic Neoplasms/drug therapy | Cancer and Oncology | Cancer och onkologi
Journal Article
Molecular cancer research, ISSN 1557-3125, 2016, Volume 14, Issue 4, pp. 324 - 331
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 23, pp. 3742 - 3748
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 24, pp. 2516 - 2527
A current standard treatment for locally advanced prostate cancer is external-beam radiotherapy combined with 3 years of androgen suppression. Adverse events,... 
TRIAL | DEPRIVATION THERAPY | IRRADIATION | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | PHASE-III | QUALITY-OF-LIFE | RADIOTHERAPY | OUTCOMES | RADIATION-THERAPY | ADJUVANT | Anilides - therapeutic use | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Flutamide - adverse effects | Treatment Failure | Aged, 80 and over | Adult | Flutamide - therapeutic use | Prostatic Neoplasms - drug therapy | Drug Administration Schedule | Proportional Hazards Models | Combined Modality Therapy | Prostatic Neoplasms - mortality | Disease-Free Survival | Tosyl Compounds - adverse effects | Heart Diseases - mortality | Tosyl Compounds - therapeutic use | Quality of Life | Radiotherapy, Conformal - adverse effects | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Heart attacks | Medical treatment | Mortality | Radiation therapy | Prostate cancer | Cancer therapies | Quality of life | Index Medicus | Abridged Index Medicus | Androgen Antagonists | Anilides | Life Sciences | Prostatic Neoplasms | Flutamide | Heart Diseases | Radiotherapy, Conformal | Gonadotropin-Releasing Hormone | Nitriles | Tosyl Compounds | Cancer
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2011, Volume 108, Issue 9, pp. 3755 - 3760
.... Previously we showed that potent synthetic antagonists of GHRH strongly inhibit the growth of diverse experimental human tumors including prostate cancer by suppressing various tumoral growth factors... 
Hormone antagonists | Receptors | Cell growth | Cytokines | Epithelial cells | Genes | Prostatic hyperplasia | Hormones | Prostate | Apoptosis | Rodent benign prostatic hyperplasia model | Prostatic hypertrophy | Chronic prostatic inflammation | Prostatic cell death | CYCLOOXYGENASE-2 | MULTIDISCIPLINARY SCIENCES | prostatic cell death | PROLIFERATION | rodent benign prostatic hyperplasia model | COMBINATION | SPLICE VARIANTS | CANCER | INHIBITION | THERAPY | prostatic hypertrophy | CELL LUNG-CARCINOMA | INFLAMMATION | chronic prostatic inflammation | EXPRESSION | Immunohistochemistry | Transcription, Genetic - drug effects | Prostatic Hyperplasia - pathology | Sermorelin - administration & dosage | Apoptosis - drug effects | Humans | Receptors, Androgen - metabolism | Male | NF-kappa B - metabolism | Receptors, Neuropeptide - metabolism | Prostate - metabolism | Inflammation - complications | Prostate - pathology | Interleukin-1beta - metabolism | Receptors, Pituitary Hormone-Regulating Hormone - metabolism | Inflammation Mediators - metabolism | Sermorelin - pharmacology | Prostate - drug effects | Sermorelin - analogs & derivatives | Gene Expression Regulation, Neoplastic - drug effects | Receptors, Pituitary Hormone-Regulating Hormone - genetics | Rats | Receptors, Neuropeptide - genetics | Signal Transduction - genetics | Down-Regulation - drug effects | Growth Hormone-Releasing Hormone - genetics | Prostatic Hyperplasia - genetics | Cell Division - drug effects | Prostate-Specific Antigen - blood | Growth Hormone-Releasing Hormone - metabolism | Organ Size - drug effects | Alternative Splicing - drug effects | Animals | Signal Transduction - drug effects | Cyclooxygenase 2 - metabolism | Inflammation - genetics | Prostatic Hyperplasia - blood | Prostatic Hyperplasia - enzymology | Growth Hormone-Releasing Hormone - antagonists & inhibitors | Insulin-Like Growth Factor I - metabolism | Genetic aspects | Polypeptides | Somatotropin releasing hormone | Health aspects | Hypertrophy | Biological Sciences
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1147 - 1154
... with prednisone is standard first-line chemotherapy in this setting. No treatment has been approved by the US Food and Drug Administration, however, for patients whose... 
Internal Medicine | EVERY 3 WEEKS | MEDICINE, GENERAL & INTERNAL | PAIN | SOLID TUMORS | END-POINTS | TAXANE | CHEMOTHERAPY | ESTRAMUSTINE | Prostatic Neoplasms - metabolism | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms - immunology | Antineoplastic Agents, Hormonal - therapeutic use | Treatment Failure | Neutropenia - chemically induced | Mitoxantrone - adverse effects | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Prostatic Neoplasms - pathology | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Biomarkers, Tumor - blood | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Infusions, Intravenous | Pain Measurement | Dosage and administration | Prednisone | Research | Drug therapy | Prostate cancer | Mitoxantrone hydrochloride | Studies | Chemotherapy | Medical imaging | Physicians | Family medical history | Radiation therapy | Clinical medicine | Cancer therapies
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 320 - 327